Marex Group’s Traws Pharma TRAW Stock Holding History

Marex Group’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,921	Closed	-$66.1K	–	781
2024 Q2	$66.1K	Hold	5,921	–	–	﹤0.01%	586
2024 Q1	$150K	Hold	5,921	–	–	﹤0.01%	406
2023 Q4	$110K	Buy	+5,921	New	+$101K	﹤0.01%	492

Other funds holding TRAW

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

VWWMG

Vermillion & White Wealth Management Group Phoenixville, Pennsylvania $198M AUM 18.6% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Marex Group's TRAW Position: Q3 2024 in Review

Marex Group sold out of Traws Pharma (TRAW) in Q3 2024, closing a stake of 5,921 shares — an estimated $66.1K sold.

Marex Group first reported a position in TRAW in Q4 2023 and held it in 3 quarters. The position peaked at $150K in Q1 2024. 12 funds tracked by Wall St. Rank hold TRAW as of Q3 2024.

Marex Group reported no remaining Traws Pharma position as of Q3 2024 after selling out during the quarter.
Marex Group sold 5,921 Traws Pharma shares in Q3 2024, an estimated $66.1K.
Marex Group first reported a position in Traws Pharma in Q4 2023 and held it in 3 quarters.
Marex Group's Traws Pharma position peaked at $150K in Q1 2024.
12 funds tracked by Wall St. Rank held Traws Pharma as of Q3 2024.

Based on Marex Group's 13F filing for Q3 2024, filed 7 Apr 2026.